Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite at the Arsmo (Hainan) Aesthetic Hospital in Boao Lecheng, China. The product follows the successful introduction of Juvederm Volux into the region under the “first pilot, first trial” policy, further expanding the company’s aesthetic portfolio in China.
Juvederm Volite: Product Overview
Juvederm Volite is an injectable implant designed to treat superficial skin depressions, such as fine lines, and to enhance skin properties, including water content and elasticity. A single treatment with Juvederm Volite can last for up to nine months, providing long-lasting aesthetic benefits for patients.
Juvederm Volux: Long-Acting Filler
In addition to Volite, Juvederm Volux, a long-acting hyaluronic acid filler, has also been commercialized in Boao Lecheng. Volux is designed to last up to 18 months with a single injection and is intended for medical and aesthetic patients over 18 years old who seek to restore or create facial volume. The first injection of a medical aesthetic product in the region took place in December 2019, with partial real-world data generated in February of the following year.-Fineline Info & Tech
